Sanofi Statistics
Total Valuation
Sanofi has a market cap or net worth of $126.26 billion. The enterprise value is $138.43 billion.
Important Dates
The next confirmed earnings date is Thursday, April 24, 2025, before market open.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | May 9, 2025 |
Share Statistics
Sanofi has 1.25 billion shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.25B |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.10B |
Valuation Ratios
The trailing PE ratio is 21.93 and the forward PE ratio is 10.93.
| PE Ratio | 21.93 |
| Forward PE | 10.93 |
| PS Ratio | 2.75 |
| Forward PS | 2.72 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 6.14 |
| P/FCF Ratio | 15.11 |
| P/OCF Ratio | 13.43 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 11.46, with an EV/FCF ratio of 16.57.
| EV / Earnings | 24.05 |
| EV / Sales | 3.02 |
| EV / EBITDA | 11.46 |
| EV / EBIT | 15.08 |
| EV / FCF | 16.57 |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.46 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 1.50 |
| Debt / FCF | 2.22 |
| Interest Coverage | 13.84 |
Financial Efficiency
Return on equity (ROE) is 7.30% and return on invested capital (ROIC) is 5.88%.
| Return on Equity (ROE) | 7.30% |
| Return on Assets (ROA) | 4.28% |
| Return on Invested Capital (ROIC) | 5.88% |
| Return on Capital Employed (ROCE) | 8.56% |
| Revenue Per Employee | $553,216 |
| Profits Per Employee | $69,455 |
| Employee Count | 82,878 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.38 |
Taxes
In the past 12 months, Sanofi has paid $1.25 billion in taxes.
| Income Tax | 1.25B |
| Effective Tax Rate | 17.82% |
Stock Price Statistics
The stock price has increased by +11.14% in the last 52 weeks. The beta is 0.48, so Sanofi's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +11.14% |
| 50-Day Moving Average | 54.87 |
| 200-Day Moving Average | 52.90 |
| Relative Strength Index (RSI) | 39.51 |
| Average Volume (20 Days) | 3,228,632 |
Short Selling Information
The latest short interest is 4.00 million, so 0.32% of the outstanding shares have been sold short.
| Short Interest | 4.00M |
| Short Previous Month | 5.61M |
| Short % of Shares Out | 0.32% |
| Short % of Float | 0.36% |
| Short Ratio (days to cover) | 1.38 |
Income Statement
In the last 12 months, Sanofi had revenue of $45.85 billion and earned $5.76 billion in profits. Earnings per share was $4.60.
| Revenue | 45.85B |
| Gross Profit | 32.19B |
| Operating Income | 9.18B |
| Pretax Income | n/a |
| Net Income | 5.76B |
| EBITDA | 12.08B |
| EBIT | 9.18B |
| Earnings Per Share (EPS) | $4.60 |
Full Income StatementBalance Sheet
The company has $7.82 billion in cash and $18.55 billion in debt, giving a net cash position of -$10.72 billion or -$8.55 per share.
| Cash & Cash Equivalents | 7.82B |
| Total Debt | 18.55B |
| Net Cash | -10.72B |
| Net Cash Per Share | -$8.55 |
| Equity (Book Value) | 80.61B |
| Book Value Per Share | 64.01 |
| Working Capital | 13.90B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $9.40 billion and capital expenditures -$1.79 billion, giving a free cash flow of $8.36 billion.
| Operating Cash Flow | 9.40B |
| Capital Expenditures | -1.79B |
| Free Cash Flow | 8.36B |
| FCF Per Share | $6.67 |
Full Cash Flow StatementMargins
Gross margin is 70.21%, with operating and profit margins of 20.03% and 12.55%.
| Gross Margin | 70.21% |
| Operating Margin | 20.03% |
| Pretax Margin | 15.26% |
| Profit Margin | 12.55% |
| EBITDA Margin | 26.34% |
| EBIT Margin | 20.03% |
| FCF Margin | 18.23% |